三联疗法治疗类风湿关节炎60例

Clinical Observation in Treating 60 Cases of Rheumatoid Arthritis with Triple Therapy

目的:观察三联疗法治疗类风湿关节炎的临床疗效和安全性,为进一步探讨中西医结合规范治疗类风湿关节炎提供临床依据。方法:将120例患者随机分成观察组和对照组。观察组采用三联疗法(中药独活寄生汤200 mL/次,2次/d辨证加减内服,中药熏洗患肢,西药柳氮磺胺吡啶肠溶片口服,第1周0.25 g/次,3次/d,第2周0.5 g/次,3次/d,第3周起0.75 g/次,3次/d,口服)综合治疗,对照组采用口服西药柳氮磺胺吡啶肠溶片第1周0.25 g/次,3次/d,第2周0.5 g/次,3次/d,第3周起0.75 g/次,3次/d,口服,联合美洛昔康75 mg,3次/d治疗,2组均治疗3个疗程。观察2组治疗前后临床症状与体征以及血沉(ESR)、类风湿因子(RF)、C反应蛋白(CRP)等实验室检测指标的改善情况。结果:与对照组相比较,观察组能显著改善临床症状与体征(P<0.01);2组治疗后均能显著性降低ESR,CRP水平,观察组疗效优于对照组(P<0.05)。结论:三联疗法治疗类风湿关节炎可取得理想的临床疗效,值得在临床推广运用。

Objective：To observe the efficiency and safety of triple therapy in the treatment of rheumatism arthritises providing the evidene for the standard treatment of rheumatoid arthritis with traditional Chinese medicine integrated with western medicine.Method：One hundred and twenty patients were randomly divided into treatment group and control group.The treatment group was treated with triple therapy including：①oral modified angelicae pubescentis andloranthi decoction;② traditional Chinese medicine fumigation;③oral salicylazosulfapyridine（SASP）.The control group was treated with oral SASP and meloxicam tablets.The treatment course was 3 months for both groups.Before and after treatment,biochemical indices such as erythrocyte sedimentation rate（ESR）,rheumatoid factor（RF）,C-reactive protein（CRP）,and other indicators of improvement.Result：Compared with the control group,the treatment groupcould significantly improve the clinical symptoms and signs（P〈0.01）,ESR and CRP also decreased significantly in the two groups after treatment.Conclusion：Triple therapy for treatment of rheumatoid arthritis can achieve the positive efficacy which would be worthy of a wide clinical application.